Fidelity Investments’s Aligos Therapeutics ALGS Stock Holding History

Fidelity Investments’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$58	Buy	+10	New	+$62	﹤0.01%	5428
2026 Q1	–	Sell	-4,972	Closed	-$46.3K	–	5418
2025 Q4	$46.3K	Buy	+4,972	New	+$46.9K	﹤0.01%	4154
2025 Q3	–	Sell	-10	Closed	-$72	–	5371
2025 Q2	$72	Buy	+10	New	+$60	﹤0.01%	5155
2023 Q4	–	Sell	-48	Closed	-$896	–	5420
2023 Q3	$896	Hold	48	–	–	﹤0.01%	4656
2023 Q2	$1.17K	Buy	48 +8	+20%	+$215	﹤0.01%	4686
2023 Q1	$874	Hold	40	–	–	﹤0.01%	4755
2022 Q4	$964	Sell	40 -1	-2%	-$25	﹤0.01%	4664
2022 Q3	$1K	Buy	41 +22	+116%	+$731	﹤0.01%	4623
2022 Q2	$1K	Sell	19 -199	-91%	-$6.76K	﹤0.01%	4656
2022 Q1	$12K	Buy	+218	New	+$17.5K	﹤0.01%	4181

Other funds holding ALGS

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Fidelity Investments's ALGS Position: Q2 2026 in Review

Fidelity Investments opened a new position in Aligos Therapeutics (ALGS) in Q2 2026: 10 shares worth $58. The stake represents ﹤0.01% of the portfolio and ranks #5428 among its holdings. This is a return to the name: Fidelity Investments previously reported a position in ALGS as recently as Q4 2025.

Fidelity Investments first reported a position in ALGS in Q1 2022 and has held it in 10 quarters since. The position peaked at $46.3K in Q4 2025. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

Fidelity Investments held 10 shares of Aligos Therapeutics worth $58 as of Q2 2026.
Aligos Therapeutics was a new Fidelity Investments position in Q2 2026.
Aligos Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #5428 holding.
Fidelity Investments first reported a position in Aligos Therapeutics in Q1 2022 and has held it in 10 quarters since.
Fidelity Investments's Aligos Therapeutics position peaked at $46.3K in Q4 2025.
31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.